Dr Andreas Schneider
Head of Innovation

Is this your profile?

About

Andreas Schneider, PhD, is Head of Innovation at Ypsomed Delivery Systems.

He leads a group that drives innovation end to end, from insights to ideas to prototypes to proof-of-concept. The team’s responsibilities range from market and technology intelligence to strategy and business development,
engineering and technology, and digital innovation. Dr Schneider has published and presented extensively in the areas of innovation management and drug delivery. He holds a PhD in Innovation Management from ETH Zurich (Switzerland).

Contributions

SUBCUTANEOUS DRUG DELIVERY: ADAPTING TO HIGH-VISCOSITY, LARGE-VOLUME DEMANDS

Thomas Fontanellaz, Reto Jost and Andreas Schneider discuss how Ypsomed is addressing the growing need for subcutaneous injections that accommodate higher volumes and viscosities, with innovative self-injection devices designed to enhance patient comfort and adherence.

More contributions

ROUNDTABLE: DISCUSSION ON ANTI-OBESITY TREATMENTS

Stephen M Perry, Mathias Romacker and Andreas Schneider tackle the subject of GLP-1s and related obesity-targeted injectable therapeutics and the enormous impact they are having and are expected still to have on drug delivery and the wider pharmaceutical sector.

HOW PATIENT & TREATMENT FACTORS SHAPE SUBCUTANEOUS DOSING PREFERENCES

Andreas Schneider highlights the importance of understanding the drivers of dosing preferences when it comes to choosing the right injection device for patients. Specifically, the research summarised here studies whether and how patient characteristics and treatment attributes influence the decision to use prefilled handheld autoinjectors or large-volume wearable injectors.

TOWARDS USER-CENTRIC SPECIFICATION OF AUTOINJECTOR TECHNICAL ATTRIBUTES: INSIGHTS FROM EMPIRICAL WORK

Andreas Schneider discusses an empirical study into both users’ ability to remove the cap from an autoinjector and the difficulty those patients perceived in doing so. The study builds a quantitative model relating the empirical data to patient perception.

HOW LONG CAN YOU HOLD THE DEVICE AGAINST THE SKIN? INSIGHTS FROM AN EMPIRICAL STUDY USING HAND-HELD AUTOINJECTORS

Andreas Schneider summarises recent empirical work investigating the ability of users of hand-held devices to complete longer injection times effectively. The study provides insights into the effects of injection duration on the force exerted by the user to hold the device against the injection site.

PAVING THE WAY TO ZERO CARBON EMISSION COMBINATION PRODUCTS: THE YPSOMATE ZERO CASE STUDY

Sebastian Gerner and Andreas Schneider discuss the relationship between the medical device industry and the global issue of plastic waste. The authors introduce YpsoMate Zero as a case study, Ypsomed’s net-zero carbon emission prefilled autoinjector.

HOW USERS DISTINGUISH BETWEEN SELF-INJECTION DEVICE PLATFORM VARIANTS

Andreas Schneider highlights how the ever-increasing interest in device platforms raises concerns around the broad availability of lookalike autoinjectors that may result in inappropriate medication usage. He summarises a recent empirical study¹ providing insights into which device attributes drive device distinguishability.

I SPY WITH MY LITTLE EYE: EYE TRACKING DRIVES PATIENT-CENTRED DEVELOPMENT OF CONNECTED SYSTEMS

The development of connected self-injection systems is driving industry to rethink its current approaches to patient-centred new product development. Andreas Schneider summarises a recent field study that used eye tracking for the formative usability testing of SmartPilot for YpsoMate.

PREFILLED SYRINGES

SIMPLE AND SECURE ADHERENCE MONITORING: YDS SMARTSERVICES™ FOR END-TO-END SMART DEVICE INTEGRATION

Whilst there is much discussion on how to apply connectivity and smart devices to therapies, there is far less dialogue concerning the challenges inherent to the digital architecture needed to make such innovations work in practice. Andreas Schneider introduces YDS SmartServices™, Ypsomed’s digital turnkey solution to effectively embed smart devices in a broader digital ecosystem.

PREFILLED SYRINGES

A NEW VALUE PROPOSITION OF SMART DEVICES: ADVANCED MEDICATION ADHERENCE MONITORING IN CLINICAL TRIALS

Andreas Schneider explores a new value proposition of smart injection systems, introducing how advanced adherence monitoring services resolve some of the key challenges of clinical research practice regarding costs, adherence, data quality and integrity, Dr Schneider explains which technical features are needed for smart devices to provide value-adding adherence monitoring services, using SmartPilot for YpsoMate as a case study.

PREFILLED SYRINGES

INSIGHTS FROM THE YPSOMATE SMART CASE STUDY

Andreas Schneider provides insights into recent development activities at Ypsomed in the area of smart self-injection systems.

PREFILLED SYRINGES

FAST & LOW-RISK CUSTOMISATION OF INNOVATIVE INJECTION SYSTEMS

Andreas Schneider highlights new emerging requirements of biopharma companies and describes how Ypsomed has established a range of innovative platform products, based on proven expertise and capabilities, and well-honed development and manufacturing processes, in order to meet its biopharma partners’ and customers’ needs fully and completely.

Top